Literature DB >> 6661362

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

O Haagen Nielsen, S Bondesen.   

Abstract

The human pharmacokinetics of 5-aminosalicylic acid (5-ASA), the active moiety of salazosulphapyridine (SASP), is only known from studies in which rapid absorption has been deliberately avoided. The present investigation demonstrates that pure 5-ASA is absorbed extremely quickly when given as an instillation in the proximal part of the small bowel, and acetylation follows immediately. The metabolite is excreted very rapidly by the liver in small amounts, while the major part is eliminated renally.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661362      PMCID: PMC1428338          DOI: 10.1111/j.1365-2125.1983.tb02254.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

2.  Distribution studies of salicylazosulfapyridine and its metabolites.

Authors:  M A Peppercorn; P Goldman
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

3.  Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silica.

Authors:  S H Hansen
Journal:  J Chromatogr       Date:  1981-12-11

4.  Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.

Authors:  K M Das; J R Chowdhury; B Zapp; J W Fara
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

5.  Nephrotoxicity and molecular structure.

Authors:  I C Calder; P J Williams; R A Woods; C C Funder; C R Green; K N Ham; J D Tange
Journal:  Xenobiotica       Date:  1975-05       Impact factor: 1.908

6.  The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.

Authors:  C P Willoughby; J Piris; S C Truelove
Journal:  Scand J Gastroenterol       Date:  1980       Impact factor: 2.423

7.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

8.  Hypertension treated by salt restriction.

Authors:  T Morgan; W Adam; A Gillies; M Wilson; G Morgan; S Carney
Journal:  Lancet       Date:  1978-02-04       Impact factor: 79.321

9.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

10.  Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.

Authors:  A K Azad Khan; S C Truelove
Journal:  Gut       Date:  1980-08       Impact factor: 23.059

View more
  36 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

3.  Paracetamol absorption from a feeding jejunostomy.

Authors:  E B Nelson; D R Abernethy; D J Greenblatt; B Ameer
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

Review 4.  Update on the management of Crohn's disease.

Authors:  Anna M Buchner; Wojciech Blonski; Gary R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2011-10

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

6.  5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.

Authors:  M B Grisham; D N Granger
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

Review 7.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

8.  Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.

Authors:  Filippos Kesisoglou; Simon Yuji Zhou; Susan Niemiec; Jordan Wing Lee; Ellen M Zimmermann; David Fleisher
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

9.  Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children.

Authors:  L A Christensen; J Fallingborg; B A Jacobsen; K Abildgaard; H H Rasmussen; S N Rasmussen; S H Hansen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

10.  Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?

Authors:  I M Nakshabendi; A Duncan; R I Russell
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.